Gene Switch Market Share, Global Industry Size, Trends, Technology, and Analysis by 2035
Gene switches have garnered significant attention from drug developers owing to their ability to control the activity of genetically modified cell products in vivo
The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.
Gene switch developers are adopting various operational models to enhance their product offerings and generate increased revenues for the firms in the future
Stakeholders have adopted various business models to maximize the gain from gene switch platforms. It is worth highlighting that a significant number of in-house players have started out-licensing their gene switch platforms. This shift in operating model is likely to generate increased revenues for the firms in the future. Several companies have adopted multiple product centric models related to gene switches; examples include Bellicum Pharmaceuticals and aceRNA Technologies.
Product competitiveness analysis - attaining a competitive edge over other products by offering advanced features- In pursuit of gaining a competitive edge, gene switch developers are presently undertaking several initiatives to expand their existing capabilities and augment respective product portfolios. The products considered in this analysis have been scored based on several relevant parameters, such as supplier strength (based on number of years of experience), product competitiveness (based on technology licensing option, application area, target therapy (s), highest phase of development and target indication).
The relative position of different products in the figure is based on the scores assigned to them for their supplier strength and product competitiveness. Based on our proprietary scoring criteria, the ZF-transcription factors developed by Sangamo Biosciences and RNA switches developed by aceRNA technologies emerged as relatively competent products, amongst all the currently available gene switch platforms. ZF-transcription factors are protein-based gene switches that are majorly used for regulation of gene expression and are activated by tamoxifen. Further, the RNA switches developed by aceRNA technologies are used for various application areas, including management of treatment related toxicity, cell proliferation / cell persistence and regulation of gene expression.
The increasing traction in the field of gene switch is evident from number of partnerships inked between stakeholder companies in the recent past- Both established players and new entrants have forged strategic partnerships in the recent past; in fact, close to 55% of the deals were signed in the last three years. Further, majority of agreements in this domain were focused on licensing of gene switches, owing to the growing safety-related concern associated with adoptive cell therapies.
It is worth noting that North America emerged as the active region, with maximum number of intracontinental deals. The future market is likely to be driven by deals inked by players based in this region. Of the total intercontinental agreements, 14% were inked with the stakeholders located in Europe. Examples of deals signed between players based in North America and Europe include (in reverse chronological order, post-2019) collaboration between panCELLa and Resolution Therapeutics (2022), Sangamo Biosciences and Novartis (July 2022) and Sangamo Biosciences and Mogrify (202.
To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/gene-switch-
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
